Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 10/20 | 0.82 |
| ▸ | PDE4A | P27815 | 13/20 | 0.76 |
| ▸ | PDE4B | Q07343 | 13/20 | 0.76 |
| ▸ | PDE4C | Q08493 | 13/20 | 0.76 |
| ▸ | PDE4D | Q08499 | 13/20 | 0.76 |
| ▸ | ADORA2B | P29275 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | BLM | P54132 | 1/20 | 0.66 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.66 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.60 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL316171 | 0.91 | PDE4A (0.82) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8912388 | 0.90 | PDE4A (0.74) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL9040437 | 0.90 | ADORA2A (0.67) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL21381260 | 0.90 | ADORA2A (1.00) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11458625 | 0.88 | PDE4A (0.73) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11471017 | 0.87 | PDE4A (0.69) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL10872056 | 0.87 | PDE4A (0.95) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11456819 | 0.87 | PDE4A (0.77) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL11466640 | 0.87 | PDE4A (0.65) | ADORA2APDE4APDE4BPDE4CPDE4D | |
| SCHEMBL8912384 | 0.86 | PDE4A (0.65) | ADORA2APDE4APDE4BPDE4CPDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-01-18 | — | — | US | disclosed |
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2019-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292186-A1 | XANTHINE DERIVATIVE INHIBITORS OF BET PROTEINS | BET1, BRD4, BRD3 | ADORA2A 3171/4885PDE4A 1873/4885PDE4B 1806/4885 |
| US-11225481-B2 | Xanthine derivative inhibitors of BET proteins | BET1, BRD4, BRD3 | ADORA2A 3171/4885PDE4A 1873/4885PDE4B 1806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.